Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.

Nanni P, Landuzzi L, Manara MC, Righi A, Nicoletti G, Cristalli C, Pasello M, Parra A, Carrabotta M, Ferracin M, Palladini A, Ianzano ML, Giusti V, Ruzzi F, Magnani M, Donati DM, Picci P, Lollini PL, Scotlandi K.

Sci Rep. 2019 Aug 21;9(1):12174. doi: 10.1038/s41598-019-48634-y.

2.

Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells.

Zwergel C, Schnekenburger M, Sarno F, Battistelli C, Manara MC, Stazi G, Mazzone R, Fioravanti R, Gros C, Ausseil F, Florean C, Nebbioso A, Strippoli R, Ushijima T, Scotlandi K, Tripodi M, Arimondo PB, Altucci L, Diederich M, Mai A, Valente S.

Clin Epigenetics. 2019 May 6;11(1):68. doi: 10.1186/s13148-019-0663-8.

3.

Oxidative Stress in Autistic Children Alters Erythrocyte Shape in the Absence of Quantitative Protein Alterations and of Loss of Membrane Phospholipid Asymmetry.

Bolotta A, Battistelli M, Falcieri E, Ghezzo A, Manara MC, Manfredini S, Marini M, Posar A, Visconti P, Abruzzo PM.

Oxid Med Cell Longev. 2018 Nov 11;2018:6430601. doi: 10.1155/2018/6430601. eCollection 2018.

4.

A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy.

Manara MC, Valente S, Cristalli C, Nicoletti G, Landuzzi L, Zwergel C, Mazzone R, Stazi G, Arimondo PB, Pasello M, Guerzoni C, Picci P, Nanni P, Lollini PL, Mai A, Scotlandi K.

Mol Cancer Ther. 2018 Sep;17(9):1881-1892. doi: 10.1158/1535-7163.MCT-17-0818. Epub 2018 Jun 29.

5.

Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Influences Sensitivity to Anti-IGF System Agents Through the Translational Regulation of IGF1R.

Mancarella C, Pasello M, Manara MC, Toracchio L, Sciandra EF, Picci P, Scotlandi K.

Front Endocrinol (Lausanne). 2018 Apr 20;9:178. doi: 10.3389/fendo.2018.00178. eCollection 2018.

6.

CD99: A Cell Surface Protein with an Oncojanus Role in Tumors.

Manara MC, Pasello M, Scotlandi K.

Genes (Basel). 2018 Mar 13;9(3). pii: E159. doi: 10.3390/genes9030159. Review.

7.

Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99.

Çelik H, Sciandra M, Flashner B, Gelmez E, Kayraklıoğlu N, Allegakoen DV, Petro JR, Conn EJ, Hour S, Han J, Oktay L, Tiwari PB, Hayran M, Harris BT, Manara MC, Toretsky JA, Scotlandi K, Üren A.

Oncogene. 2018 Apr;37(16):2181-2196. doi: 10.1038/s41388-017-0080-4. Epub 2018 Jan 31.

PMID:
29382926
8.

CD99 at the crossroads of physiology and pathology.

Pasello M, Manara MC, Scotlandi K.

J Cell Commun Signal. 2018 Mar;12(1):55-68. doi: 10.1007/s12079-017-0445-z. Epub 2018 Jan 6. Review.

9.

Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors.

Ratti C, Botti L, Cancila V, Galvan S, Torselli I, Garofalo C, Manara MC, Bongiovanni L, Valenti CF, Burocchi A, Parenza M, Cappetti B, Sangaletti S, Tripodo C, Scotlandi K, Colombo MP, Chiodoni C.

Clin Cancer Res. 2017 Sep 1;23(17):5149-5161. doi: 10.1158/1078-0432.CCR-16-3186. Epub 2017 Jun 9.

10.

Targeting ROCK2 rather than ROCK1 inhibits Ewing sarcoma malignancy.

Pinca RS, Manara MC, Chiadini V, Picci P, Zucchini C, Scotlandi K.

Oncol Rep. 2017 Mar;37(3):1387-1393. doi: 10.3892/or.2017.5397. Epub 2017 Jan 20.

11.

CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling.

Manara MC, Terracciano M, Mancarella C, Sciandra M, Guerzoni C, Pasello M, Grilli A, Zini N, Picci P, Colombo MP, Morrione A, Scotlandi K.

Oncotarget. 2016 Nov 29;7(48):79925-79942. doi: 10.18632/oncotarget.13160.

12.

Process development of a human recombinant diabody expressed in E. coli: engagement of CD99-induced apoptosis for target therapy in Ewing's sarcoma.

Moricoli D, Carbonella DC, Dominici S, Fiori V, Balducci MC, Guerzoni C, Manara MC, Pasello M, Laguardia ME, Cianfriglia M, Scotlandi K, Magnani M.

Appl Microbiol Biotechnol. 2016 May;100(9):3949-63. doi: 10.1007/s00253-015-7226-5. Epub 2015 Dec 21.

PMID:
26685854
13.

CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-κB signaling.

Ventura S, Aryee DN, Felicetti F, De Feo A, Mancarella C, Manara MC, Picci P, Colombo MP, Kovar H, Carè A, Scotlandi K.

Oncogene. 2016 Jul 28;35(30):3944-54. doi: 10.1038/onc.2015.463. Epub 2015 Nov 30.

14.

ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents.

Mancarella C, Casanova-Salas I, Calatrava A, Ventura S, Garofalo C, Rubio-Briones J, Magistroni V, Manara MC, López-Guerrero JA, Scotlandi K.

Oncotarget. 2015 Jun 30;6(18):16611-22.

15.

Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.

Amaral AT, Garofalo C, Frapolli R, Manara MC, Mancarella C, Uboldi S, Di Giandomenico S, Ordóñez JL, Sevillano V, Malaguarnera R, Picci P, Hassan AB, De Alava E, D'Incalci M, Scotlandi K.

Clin Cancer Res. 2015 Mar 15;21(6):1373-82. doi: 10.1158/1078-0432.CCR-14-1688. Epub 2015 Jan 21.

16.

CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin.

Guerzoni C, Fiori V, Terracciano M, Manara MC, Moricoli D, Pasello M, Sciandra M, Nicoletti G, Gellini M, Dominici S, Chiodoni C, Fornasari PM, Lollini PL, Colombo MP, Picci P, Cianfriglia M, Magnani M, Scotlandi K.

Clin Cancer Res. 2015 Jan 1;21(1):146-56. doi: 10.1158/1078-0432.CCR-14-0492. Epub 2014 Dec 11.

17.

Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression.

Marino MT, Grilli A, Baricordi C, Manara MC, Ventura S, Pinca RS, Bellenghi M, Calvaruso M, Mattia G, Donati D, Tripodo C, Picci P, Ferrari S, Scotlandi K.

Ann Oncol. 2014 Oct;25(10):2080-6. doi: 10.1093/annonc/mdu249. Epub 2014 Jul 10.

PMID:
25015333
18.

CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2.

Sciandra M, Marino MT, Manara MC, Guerzoni C, Grano M, Oranger A, Lucarelli E, Lollini PL, Dozza B, Pratelli L, Renzo MF, Colombo MP, Picci P, Scotlandi K.

J Bone Miner Res. 2014;29(5):1295-309. doi: 10.1002/jbmr.2141.

19.

An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas.

Guerzoni C, Amatori S, Giorgi L, Manara MC, Landuzzi L, Lollini PL, Tassoni A, Balducci M, Manfrini M, Pratelli L, Serra M, Picci P, Magnani M, Fusi V, Fanelli M, Scotlandi K.

BMC Cancer. 2014 Feb 27;14:137. doi: 10.1186/1471-2407-14-137.

20.

Characterization of human mesenchymal stem cells from ewing sarcoma patients. Pathogenetic implications.

Amaral AT, Manara MC, Berghuis D, Ordóñez JL, Biscuola M, Lopez-García MA, Osuna D, Lucarelli E, Alviano F, Lankester A, Scotlandi K, de Álava E.

PLoS One. 2014 Feb 3;9(2):e85814. doi: 10.1371/journal.pone.0085814. eCollection 2014. Erratum in: PLoS One.2014;9(4):e94455.

21.

Expression levels of insulin receptor substrate-1 modulate the osteoblastic differentiation of mesenchymal stem cells and osteosarcoma cells.

Contaldo C, Myers TJ, Zucchini C, Manara MC, Chiodoni C, Colombo MP, Nicoletti G, Lollini PL, Li T, Longobardi L, Scotlandi K, Spagnoli A.

Growth Factors. 2014 Feb;32(1):41-52. doi: 10.3109/08977194.2013.870168. Epub 2014 Jan 20.

PMID:
24438070
22.

Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug.

Garofalo C, Capristo M, Manara MC, Mancarella C, Landuzzi L, Belfiore A, Lollini PL, Picci P, Scotlandi K.

PLoS One. 2013 Dec 31;8(12):e83832. doi: 10.1371/journal.pone.0083832. eCollection 2013.

23.

CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity.

Zucchini C, Manara MC, Pinca RS, De Sanctis P, Guerzoni C, Sciandra M, Lollini PL, Cenacchi G, Picci P, Valvassori L, Scotlandi K.

Oncogene. 2014 Apr 10;33(15):1912-21. doi: 10.1038/onc.2013.152. Epub 2013 May 6.

PMID:
23644663
24.

Designing novel therapies against sarcomas in the era of personalized medicine and economic crisis.

Manara MC, Garofalo C, Ferrari S, Belfiore A, Scotlandi K.

Curr Pharm Des. 2013;19(30):5344-61. Review.

PMID:
23394085
25.

miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control.

Novello C, Pazzaglia L, Cingolani C, Conti A, Quattrini I, Manara MC, Tognon M, Picci P, Benassi MS.

Int J Oncol. 2013 Feb;42(2):667-75. doi: 10.3892/ijo.2012.1717. Epub 2012 Nov 28.

PMID:
23229283
26.

Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma.

Garofalo C, Mancarella C, Grilli A, Manara MC, Astolfi A, Marino MT, Conte A, Sigismund S, Carè A, Belfiore A, Picci P, Scotlandi K.

Mol Endocrinol. 2012 Sep;26(9):1603-16. doi: 10.1210/me.2012-1142. Epub 2012 Jul 13.

27.

Generation of human single-chain antibody to the CD99 cell surface determinant specifically recognizing Ewing's sarcoma tumor cells.

Gellini M, Ascione A, Flego M, Mallano A, Dupuis ML, Zamboni S, Terrinoni M, D'Alessio V, Manara MC, Scotlandi K, Picci P, Cianfriglia M.

Curr Pharm Biotechnol. 2013;14(4):449-63.

PMID:
22335486
28.

miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy.

Nakatani F, Ferracin M, Manara MC, Ventura S, Del Monaco V, Ferrari S, Alberghini M, Grilli A, Knuutila S, Schaefer KL, Mattia G, Negrini M, Picci P, Serra M, Scotlandi K.

J Pathol. 2012 Apr;226(5):796-805. doi: 10.1002/path.3007.

PMID:
21960059
29.

Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy.

Pasello M, Manara MC, Michelacci F, Fanelli M, Hattinger CM, Nicoletti G, Landuzzi L, Lollini PL, Caccuri A, Picci P, Scotlandi K, Serra M.

Anal Cell Pathol (Amst). 2011;34(3):131-45. doi: 10.3233/ACP-2011-012.

30.

Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival.

Scotlandi K, Manara MC, Serra M, Marino MT, Ventura S, Garofalo C, Alberghini M, Magagnoli G, Ferrari S, Lopez-Guerrero JA, Llombard-Bosch A, Picci P.

Eur J Cancer. 2011 May;47(8):1258-66. doi: 10.1016/j.ejca.2011.01.007. Epub 2011 Feb 21.

PMID:
21345666
31.

Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling.

Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, Astolfi A, Pandini G, López-Guerrero JA, Schaefer KL, Belfiore A, Picci P, Scotlandi K.

Oncogene. 2011 Jun 16;30(24):2730-40. doi: 10.1038/onc.2010.640. Epub 2011 Jan 31.

PMID:
21278796
32.

Xg expression in Ewing's sarcoma is of prognostic value and contributes to tumor invasiveness.

Meynet O, Scotlandi K, Pradelli E, Manara MC, Colombo MP, Schmid-Antomarchi H, Picci P, Bernard A, Bernard G.

Cancer Res. 2010 May 1;70(9):3730-8. doi: 10.1158/0008-5472.CAN-09-2837. Epub 2010 Apr 13.

33.

CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis.

Rocchi A, Manara MC, Sciandra M, Zambelli D, Nardi F, Nicoletti G, Garofalo C, Meschini S, Astolfi A, Colombo MP, Lessnick SL, Picci P, Scotlandi K.

J Clin Invest. 2010 Mar;120(3):668-80. doi: 10.1172/JCI36667. Epub 2010 Feb 8.

34.

NVP-BEZ235 as a new therapeutic option for sarcomas.

Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, García-Echeverría C, Mercuri M, Picci P, Scotlandi K.

Clin Cancer Res. 2010 Jan 15;16(2):530-40. doi: 10.1158/1078-0432.CCR-09-0816. Epub 2010 Jan 12.

35.

Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target.

Pantaleo MA, Astolfi A, Di Battista M, Heinrich MC, Paterini P, Scotlandi K, Santini D, Catena F, Manara MC, Nannini M, Maleddu A, Saponara M, Lolli C, Formica S, Biasco G.

Int J Cancer. 2009 Dec 15;125(12):2991-4. doi: 10.1002/ijc.24595.

36.

Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP).

Zambelli D, Zuntini M, Nardi F, Manara MC, Serra M, Landuzzi L, Lollini PL, Ferrari S, Alberghini M, Llombart-Bosch A, Piccolo E, Iacobelli S, Picci P, Scotlandi K.

Int J Cancer. 2010 Jan 1;126(1):41-52. doi: 10.1002/ijc.24670.

37.

Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome.

Scotlandi K, Remondini D, Castellani G, Manara MC, Nardi F, Cantiani L, Francesconi M, Mercuri M, Caccuri AM, Serra M, Knuutila S, Picci P.

J Clin Oncol. 2009 May 1;27(13):2209-16. doi: 10.1200/JCO.2008.19.2542. Epub 2009 Mar 23.

PMID:
19307502
38.

Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma.

Scionti I, Michelacci F, Pasello M, Hattinger CM, Alberghini M, Manara MC, Bacci G, Ferrari S, Scotlandi K, Picci P, Serra M.

Ann Oncol. 2008 Aug;19(8):1500-8. doi: 10.1093/annonc/mdn148. Epub 2008 Apr 2.

PMID:
18385200
39.

Apoptotic genes as potential markers of metastatic phenotype in human osteosarcoma cell lines.

Zucchini C, Rocchi A, Manara MC, De Sanctis P, Capanni C, Bianchini M, Carinci P, Scotlandi K, Valvassori L.

Int J Oncol. 2008 Jan;32(1):17-31.

PMID:
18097539
40.

Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling.

Cantiani L, Manara MC, Zucchini C, De Sanctis P, Zuntini M, Valvassori L, Serra M, Olivero M, Di Renzo MF, Colombo MP, Picci P, Scotlandi K.

Cancer Res. 2007 Aug 15;67(16):7675-85.

41.

CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity.

Scotlandi K, Zuntini M, Manara MC, Sciandra M, Rocchi A, Benini S, Nicoletti G, Bernard G, Nanni P, Lollini PL, Bernard A, Picci P.

Oncogene. 2007 Oct 11;26(46):6604-18. Epub 2007 Apr 30.

PMID:
17471235
42.

Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.

Manara MC, Landuzzi L, Nanni P, Nicoletti G, Zambelli D, Lollini PL, Nanni C, Hofmann F, García-Echeverría C, Picci P, Scotlandi K.

Clin Cancer Res. 2007 Feb 15;13(4):1322-30.

43.

Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells.

Benassi MS, Chiechi A, Ponticelli F, Pazzaglia L, Gamberi G, Zanella L, Manara MC, Perego P, Ferrari S, Picci P.

Cancer Lett. 2007 Jun 8;250(2):194-205. Epub 2006 Nov 20.

PMID:
17113707
44.

May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol.

Serra M, Pasello M, Manara MC, Scotlandi K, Ferrari S, Bertoni F, Mercuri M, Alvegard TA, Picci P, Bacci G, Smeland S.

Int J Oncol. 2006 Dec;29(6):1459-68.

PMID:
17088985
45.

RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cells.

Strillacci A, Griffoni C, Spisni E, Manara MC, Tomasi V.

Br J Cancer. 2006 May 8;94(9):1300-10.

46.

Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma.

Benini S, Zuntini M, Manara MC, Cohen P, Nicoletti G, Nanni P, Oh Y, Picci P, Scotlandi K.

Int J Cancer. 2006 Sep 1;119(5):1039-46.

47.

CD99 acts as an oncosuppressor in osteosarcoma.

Manara MC, Bernard G, Lollini PL, Nanni P, Zuntini M, Landuzzi L, Benini S, Lattanzi G, Sciandra M, Serra M, Colombo MP, Bernard A, Picci P, Scotlandi K.

Mol Biol Cell. 2006 Apr;17(4):1910-21. Epub 2006 Jan 18.

48.

Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma.

Scotlandi K, Perdichizzi S, Bernard G, Nicoletti G, Nanni P, Lollini PL, Curti A, Manara MC, Benini S, Bernard A, Picci P.

Eur J Cancer. 2006 Jan;42(1):91-6. Epub 2005 Dec 2.

PMID:
16326096
49.

The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71.

Manara MC, Perdichizzi S, Serra M, Pierini R, Benini S, Hattinger CM, Astolfi A, Bagnati R, D'Incalci M, Picci P, Scotlandi K.

Int J Oncol. 2005 Dec;27(6):1605-16.

PMID:
16273217
50.

4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients.

Pasello M, Hattinger CM, Stoico G, Manara MC, Benini S, Geroni C, Mercuri M, Scotlandi K, Picci P, Serra M.

Eur J Cancer. 2005 Sep;41(14):2184-95.

PMID:
16140527

Supplemental Content

Loading ...
Support Center